ITC Ends Investigation on Hydrodermabrasion Systems After Complainant Withdraws
The International Trade Commission has ended a Section 337 investigation on imports of hydrodermabrasion systems (ITC Inv. No. 337-TA-1416), it said in a notice to be published March 18. Complainant HydraFacial initially alleged in 2024 that Sinclair Pharma’s U.S. and U.K. branches, as well as Huadong Medicine, EMA Aesthetics, Aesthetics Management Partners, Advanced Aesthetics Services and H.R. Meditech, are infringing patents related to HydraFacial’s systems for skin treatment through mechanical or fluid-based abrasion or exfoliation (see 2409100036).
Sign up for a free preview to unlock the rest of this article
Communications Daily is required reading for senior executives at top telecom corporations, law firms, lobbying organizations, associations and government agencies (including the FCC). Join them today!
On Feb. 18, HydraFacial filed an unopposed motion to "terminate this investigation based on withdrawal of the complaint," and confirmed that it had conferred with the respondents prior to filing the motion. Shortly thereafter, the administrative law judge initially granted the request and the ITC voted on March 11 not to review the termination, ending the investigation.